Page last updated: 2024-11-06

oltipraz

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oltipraz is a synthetic compound with anti-cancer properties. It is a derivative of dithiocarbamate and has been studied for its potential to inhibit the growth of various types of cancer cells, including leukemia, lung cancer, and breast cancer. Oltipraz's mechanism of action is believed to involve the induction of apoptosis, the process of programmed cell death, and the inhibition of angiogenesis, the formation of new blood vessels. It has also been shown to inhibit the activation of NF-κB, a transcription factor that plays a role in inflammation and cancer progression. Oltipraz has been investigated in clinical trials as a potential treatment for cancer, but further research is needed to determine its safety and efficacy in humans. Oltipraz is also being studied for its potential to prevent cancer and other diseases. It is important to note that Oltipraz is not currently approved by the Food and Drug Administration (FDA) for the treatment or prevention of any disease.'

oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47318
CHEMBL ID178459
CHEBI ID77319
SCHEMBL ID241164
MeSH IDM0086329

Synonyms (67)

Synonym
AB01275510-01
NCI60_003092
rp-35972
4-methyl-5-pyrazin-2-yl-3h-1,2-dithiole-3-thione
c8h6n2s3
oltipraz [inn]
3h-1,2-dithiole-3-thione, 4-methyl-5-pyrazinyl-
ccris 4048
5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione
4-methyl-5-pyrazinyl-3h-1,2-dithiole-3-thione
brn 0978110
nsc 347901
rp 35972
einecs 264-736-6
oltiprazum [inn-latin]
3h-1, 4-methyl-5-pyrazinyl-
64224-21-1
nsc347901
oltipraz
nsc-347901
OLT ,
4-methyl-5-(pyrazinyl)-3h-1,2-dithiole-3-thione
rp-35,972
HMS2090F09
4-methyl-5-pyrazin-2-yldithiole-3-thione
CHEMBL178459
chebi:77319 ,
pharmakon1600-01502317
nsc759840
nsc-759840
AKOS015950809
bdbm50418081
unii-6n510jul1y
6n510jul1y ,
oltiprazum
FT-0630745
AS-7036
4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione
oltipraz [who-dd]
SCHEMBL241164
CCG-213819
DL-106
MLS006011663
smr001550500
4-methyl-5-(2-pyrazinyl)-3h-1,2-dithiole-3-thione
CKNAQFVBEHDJQV-UHFFFAOYSA-N
AB01275510_02
mfcd00868499
DTXSID7021079
HY-12519
CS-5412
EX-A646
SR-05000001517-1
sr-05000001517
oltipraz, >=98% (hplc), powder
DB12539
BCP16064
S7864
Q7088765
A13164
SB17336
rp 35972;nsc 347901
H10964
NCGC00387263-05
AC-36811
4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione;3h-1,2-dithiole-3-thione,4-methyl-5-(2-pyrazinyl)-
A867929

Research Excerpts

Overview

Oltipraz is a cancer chemopreventive agent and has an inhibitory effect on angiogenesis and tumor growth. It is a slow-acting drug and approximately 2 months are required until its full schistosomicidal effect becomes evident.

ExcerptReferenceRelevance
"Oltipraz is a synthetic dithiolethione with an antisteatotic effect by inhibiting the activity of liver X receptor alpha (LXR-α). "( Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S, 2017
)
2.15
"Oltipraz is a cancer chemopreventive agent and has an inhibitory effect on angiogenesis and tumor growth."( Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.
Brooks, SC; Choi, JH; Kim, SG; Kim, YW; Lee, MO; Lee, WH, 2009
)
2.52
"Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). "( Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Cho, SH; Choi, JY; Choi, YH; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, MG; Lee, YS; Um, SH; Yu, ES, 2010
)
2.13
"Oltipraz is a bifunctional inducer, modulating both phase I and II drug-metabolizing enzymes to enhance carcinogen detoxification."( Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element.
Batist, G; Hu, L; Kandouz, M; Miao, W, 2003
)
2.48
"Oltipraz (OPZ) is a known inducer of glutathione S-transferases and a mechanism-based inhibitor of cytochrome P450 1A2. "( Oltipraz, 3H-1,2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells.
Chun, JA; Furge, LL; Haab, BB; Haddad, R; Klenow, S; Konwinski, RR; Larson, SC, 2004
)
3.21
"Oltipraz (OPZ) is a well known inducer of NAD(P)H:quinone oxidoreductase (NQO1) along with other enzymes that comprise the nuclear factor E2-related factor 2 (Nrf2) battery of detoxification genes. "( The Nrf2 activator oltipraz also activates the constitutive androstane receptor.
Augustine, LM; Cherrington, NJ; Fisher, CD; Huang, W; Jackson, JP; Klaassen, CD; Maher, JM; Merrell, MD; Moore, DD; Slitt, AL; Zhang, Y, 2008
)
2.12
"Oltipraz thus appears to be a most interesting drug for urinary schistosomiasis"( [Results obtained on S. haematobium by Oltipraz in Niger (author's transl)].
Charmot, G; Rey, JL; Sellin, B; Simonkovich, E,
)
1.12
"Oltipraz is a slow-acting drug and approximately 2 months are required until its full schistosomicidal effect becomes evident."( The antischistosomal activity of oltipraz.
Bueding, E; Dolan, P; Leroy, JP, 1982
)
1.27
"Oltipraz (OPZ) is a potent chemopreventive agent against chemically-induced carcinogenesis in several animal models. "( Differential effects of oltipraz on CYP1A and CYP2B in rat lung.
Bardiau, C; Courtois, A; Guillouzo, A; Ilyin, G; Le Ferrec, E; Mahéo, K; Morel, F, 2001
)
2.06
"Oltipraz is a cancer chemopreventive agent active against a wide variety of chemical carcinogens. "( Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression.
Choi, SH; Ha, JR; Kang, KW; Kim, CW; Kim, SG, 2002
)
1.97
"Oltipraz is an antioxidant which is structurally related to compounds found in cruciferous vegetables."( Changes in endogenous DNA damage in aging mice in response to butylated hydroxyanisole and oltipraz.
Lawson, T; Stohs, S, 1985
)
1.21

Effects

Oltipraz is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. It promotes phosphatidylinositol 3-kinase-mediated activation of CCAAT/enhancer binding protein-beta (C/EBPbeta) Treatment has significant protective effect in testicular ischaemia/reperfusion damage.

ExcerptReferenceRelevance
"Oltipraz treatment has significant protective effect in testicular ischaemia/reperfusion damage."( Protective effect of oltipraz in testicular ischaemia/reperfusion injury: An experimental study.
Acar, E; Altunrende, F; Can, O; Canat, L; Eraldemir, FC; Otunctemur, A; Sonmez, K; Yildirim, F, 2022
)
1.76
"Oltipraz has other therapeutic potentials, which include anti-fibrotic effect, inhibition of insulin resistance, mitochondrial protection and cytoprotective effect against oxidative stress."( Antioxidant and mitochondrial protective effects of oxidized metabolites of oltipraz.
Choi, SH; Kim, SG; Kim, YM; Lee, JM, 2010
)
1.31
"Oltipraz has been reported to induce phase II drug-metabolizing enzymes."( Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.
Contreras, ML; Crowell, J; Dimitrov, NV; Madhukar, BV; Meyer-Leece, C, 2002
)
1.25
"Oltipraz, which has been extensively studied as a cancer chemopreventive agent, promotes phosphatidylinositol 3-kinase-mediated activation of CCAAT/enhancer binding protein-beta (C/EBPbeta). "( Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation.
Kim, SG; Lee, SJ, 2006
)
2.05
"Oltipraz has been used to treat schistosomiasis in humans and is undergoing clinical evaluation as an anticarcinogen."( Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.
Baron, P; Polsky, B; Prochaska, HJ; Yeh, Y, 1993
)
2.45
"Oltipraz has shown chemopreventive efficacy in numerous laboratory epithelial cancer models and is a potential chemopreventive, antimutagenic compound that specifically induces Phase II enzymes."( Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent.
Crowell, JA; Goldenthal, EI; Hall, LB; Heath, JE; Kelloff, GJ; Page, JG; Rodman, LE, 1997
)
1.02
"Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. "( Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
Chen, B; Davidson, NE; De Flora, S; Egner, PA; Enger, CL; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; He, X; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wang, JS; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR, 1997
)
3.18

Treatment

Oltipraz treatment in BDL mice enhanced α-smooth muscle actin expression, consistent with activation of hepatic stellate cells and portal fibroblasts. Treatment should be avoided as therapy for extrahepatic cholestatic disorders due to bile duct obstruction.

ExcerptReferenceRelevance
"Oltipraz treatment has significant protective effect in testicular ischaemia/reperfusion damage."( Protective effect of oltipraz in testicular ischaemia/reperfusion injury: An experimental study.
Acar, E; Altunrende, F; Can, O; Canat, L; Eraldemir, FC; Otunctemur, A; Sonmez, K; Yildirim, F, 2022
)
1.76
"Oltipraz treatment in BDL mice enhanced α-smooth muscle actin expression, consistent with activation of hepatic stellate cells and portal fibroblasts."( Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Boyer, JL; Harry, K; Luo, Y; Mennone, A; Soroka, CJ; Weerachayaphorn, J, 2014
)
1.44
"Oltipraz treatment exacerbates the severity of liver injury following BDL and should be avoided as therapy for extrahepatic cholestatic disorders due to bile duct obstruction."( Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Boyer, JL; Harry, K; Luo, Y; Mennone, A; Soroka, CJ; Weerachayaphorn, J, 2014
)
2.16
"Oltipraz treatment effectively inhibited mitochondrial permeability transition promoted by AA + iron in HepG2 cells, thereby protecting cells from ROS-induced apoptosis."( Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners.
Kim, SG; Shin, SM, 2009
)
1.29
"Oltipraz treatment (30 mg/kg/day, for 3 days) promoted liver regeneration in PH rats, but did not increase hepatocyte growth factor production."( Oltipraz promotion of liver regeneration after partial hepatectomy: The role of PI3-kinase-dependent C/EBPbeta and cyclin E regulation.
Cho, IJ; Kang, KW; Kim, SG; Sung, DK, 2009
)
2.52
"Oltipraz treatment abrogated insulin-induced H(2)O(2) production, thereby preventing H(2)O(2)-enhanced HIF-1alpha expression and promoting its ubiquitination and degradation."( Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.
Brooks, SC; Choi, JH; Kim, SG; Kim, YW; Lee, MO; Lee, WH, 2009
)
2.52
"In oltipraz-treated cells, C/EBPbeta translocated to the nucleus and bound to the consensus sequence of C/EBP (TTGCGCAA)."( Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz.
Cho, IJ; Kang, KW; Kim, SG; Lee, CH, 2003
)
1.03
"Oltipraz treatment at 1 or 48 h before B[a]P had no protective effect on forestomach tetrol levels in nrf2-deficient mice, whereas a significant reduction was observed in wild-type mice treated with oltipraz 48 h, but not 1 h, before carcinogen."( Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice.
Dolan, PM; Itoh, K; Kensler, TW; Ramos-Gomez, M; Yamamoto, M, 2003
)
1.31
"Oltipraz treatment of both HCT116 and HT29 cells results in the induction of proteins involved in both pathways of NF-kappaB activation, including p65, IkappaB kinase alpha (IKKalpha), IkappaB kinase beta (IKKbeta), and NF-kappaB-inducing kinase (NIK)."( NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling.
Nho, CW; O'Dwyer, PJ, 2004
)
1.29
"Oltipraz treatment was most effective in this regard followed by flavone and indole-3-carbinol."( Induction of phase-1 metabolizing enzymes by oltipraz, flavone and indole-3-carbinol enhance the formation and transport of benzo[a]pyrene sulfate conjugates in intestinal Caco-2 cells.
Ebert, B; Lampen, A; Seidel, A, 2005
)
1.31
"Oltipraz treatment approximately 3-fold elevated the ratio of LIP to LAP."( Enhanced CCAAT/enhancer-binding protein beta-liver-enriched inhibitory protein production by Oltipraz, which accompanies CUG repeat-binding protein-1 (CUGBP1) RNA-binding protein activation, leads to inhibition of preadipocyte differentiation.
Bae, EJ; Kim, SG, 2005
)
1.27
"Oltipraz treatment led to increases in the catalytic activity and nuclear translocation of RSK1, which was abrogated by PI3-kinase inhibition."( Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation.
Kim, SG; Lee, SJ, 2006
)
1.33
"Oltipraz treatment inhibited the ability of TNF-alpha to activate p70 ribosomal S6 kinase-1 (S6K1) downstream of mammalian target of rapamycin, thus preventing insulin receptor substrate-1 serine phosphorylation and protecting insulin signals."( Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway.
Bae, EJ; Kim, JW; Kim, SG; Yang, YM, 2007
)
1.06
"When treated with oltipraz, they had reduced macrophage infiltration proinflammatory cytokines and MMPs."( Oltipraz, the activator of nuclear factor erythroid 2-related factor 2 (Nrf2), protects against the formation of BAPN-induced aneurysms and dissection of the thoracic aorta in mice by inhibiting activation of the ROS-mediated NLRP3 inflammasome.
Chen, X; Du, X; Huang, X; Le, S; Li, R; Luo, J; Song, Y; Wang, D; Wang, H; Wu, J; Wu, L; Ye, P, 2022
)
2.49
"G1c: treated with Oltipraz (Oz) in a dose of 500 mg/kg for three consecutive days."( Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy, GH, 2009
)
0.88
"Treatment with oltipraz increased GST and NQR activities by approximately 21% and 11%, respectively."( Protection of retinal pigment epithelial cells from oxidative damage by oltipraz, a cancer chemopreventive agent.
Armstrong, JS; Cai, J; Jones, DP; Moriarty, S; Nelson, KC; Sternberg, P; Wu, MW, 2002
)
0.89
"Pretreatment of oltipraz, 5, and 6 in cell culture media with 1 mM GSH, which is shown to immediately convert 5 and 6 to 4, followed by incubation with Hepa 1c1c7 cells shows similar potencies for oltipraz and the (decomposed) produrgs, with CD(NQO1) = 18.0 +/- 4.4 microM for 5, 17.8 +/- 0.2 microM for 6, and 13.5 +/- 1.4 microM for oltipraz."( Phase 2 enzyme induction by the major metabolite of oltipraz.
Fishbein, JC; Johnson, JK; Kensler, TW; Kwak, MK; Navamal, M; Petzer, JP, 2003
)
0.9
"The treatment by oltipraz (RP 35972) had a 91.9% success rate in Klonou (similar to our results in Paris)."( [Epidemiologic study of 2 foci of Schistosoma mansoni bilharziasis in Togo (Lama Kara and Kpalimé). Comparative efficacy of oltipraz (RP 35972)].
Agbo, K; Amedome, A; Ancelle, T; Dupouy-Camet, J; Faurant, C; Heyer, F; Kotor, T; Lapierre, J; Tourte-Schaefer, C,
)
0.67
"Treatment with oltipraz, an inducer of GST Alpha, partially overcomes the effect of HBx on both promoters."( Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz.
Alaoui-Jamali, MA; Batist, G; Fotouhi-Ardakani, N; Jaitovitch-Groisman, I; Schecter, RL; Woo, A, 2000
)
0.86
"Treatment with oltipraz at all doses reduced by greater than 90% the volume of liver occupied by gamma-glutamyl transpeptidase-positive foci."( Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones.
Dolan, PM; Egner, PA; Groopman, JD; Kensler, TW; Roebuck, BD, 1987
)
0.82

Toxicity

ExcerptReferenceRelevance
" Taken together, these results indicate that oltipraz is very effective in ameliorating the toxic effects of AFB1 in rats."( Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat.
Groopman, JD; Kensler, TW; Liu, YL; Roebuck, BD; Yager, JD, 1988
)
0.78
"Administration of tert-butyl-4-hydroxyanisole or of two dithiolthiones to female CD-1 mice protected against the acute toxic effects of two hepatotoxic agents, acetaminophen and carbon tetrachloride."( Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity.
Ansher, SS; Bueding, E; Dolan, P,
)
0.13
" We concluded that NAC/OLZ modulates some end points related to GSH but is too toxic for chemoprevention at the doses used."( Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.
Bolanowska-Higdon, W; Creaven, PJ; Hitt, S; Lawrence, D; Murphy, M; Pendyala, L; Schwartz, G; Zdanowicz, J, 2001
)
0.56
" The incidence of adverse events was comparable among groups."( Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S, 2017
)
0.7

Pharmacokinetics

Oltipraz was given intravenously (10 mg x kg(-1) or orally (30mg x kg (-1) to rats with liver cirrhosis and diabetes. The pharmacokinetic parameters of oltipaz did not significantly altered by silymarin. It would be expected that in PCM rats, some pharmacokinetics parameters are fully or partially returned to controls by cysteine.

ExcerptReferenceRelevance
" There were indications of dose-dependent pharmacokinetic properties because apparent clearance and volume of distribution at steady state increased with dose, although these changes were not statistically significant as a result of high interpatient variability."( Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.
Brennan, JM; Gallo, JM; Laub, PB; O'Dwyer, PJ; Szarka, C, 2000
)
0.57
" The objective was to study toxicity and the modulation of pharmacodynamic end points."( Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.
Bolanowska-Higdon, W; Creaven, PJ; Hitt, S; Lawrence, D; Murphy, M; Pendyala, L; Schwartz, G; Zdanowicz, J, 2001
)
0.56
"The aim of this study was to report the pharmacokinetic interaction between oltipraz (50 mg kg(-1)) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB, 10 mg kg(-1)) after single intravenous and oral administration to rats."( Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats.
Bae, SK; Chung, SJ; Kim, EJ; Kim, SG; Lee, MG, 2003
)
0.82
" Interspecies scale-up of plasma concentration-time data for the four species using pharmacokinetic time of dienetichron resulted in similar profiles."( Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae, SK; Kim, JW; Kim, SH; Kim, T; Kim, YG; Lee, MG; Lee, SJ, 2005
)
0.6
" Hence, it would be expected that in PCM rats, some pharmacokinetic parameters of oltipraz are fully or partially returned to controls by cysteine."( Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition.
Bae, SK; Kim, JW; Kim, T; Kwon, JW; Lee, MG; Yang, SH, 2005
)
0.81
"Oltipraz was given intravenously (10 mg x kg(-1)) or orally (30 mg x kg(-1)) to rats with liver cirrhosis induced by N-dimethylnitrosamine (LC rats) or with diabetes, induced by streptozotocin (DM rats) or to rats with both liver cirrhosis and diabetes (LCD rats) and to control rats, and pharmacokinetic variables measured."( Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.
Ahn, CY; Bae, SH; Bae, SK; Jung, YS; Kim, T; Kim, YC; Lee, MG; Shin, WG, 2009
)
2.12
"To evaluate the pharmacokinetic interaction between oltipraz and silymarin after intravenous and oral administration of both drugs to male Sprague-Dawley rats."( Pharmacokinetic interaction between oltipraz and silymarin in rats.
Bae, SK; Kang, MK; Kim, JW; Lee, MG, 2009
)
0.88
"The pharmacokinetic parameters of oltipraz did not significantly altered by silymarin."( Pharmacokinetic interaction between oltipraz and silymarin in rats.
Bae, SK; Kang, MK; Kim, JW; Lee, MG, 2009
)
0.91
" In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (C(max)), and terminal half-life (t(1/2)) of oltipraz as well as the AUC of its RM were dose dependent."( Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Cho, SH; Choi, JY; Choi, YH; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, MG; Lee, YS; Um, SH; Yu, ES, 2010
)
0.88
" The applicability of the assay to pharmacokinetic studies was also evaluated."( Quantification of oltipraz using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in rat plasma.
Jin, QR; Kim, CY; Kim, DG; Lee, GW; Lee, JH; Lee, KR; Lim, H; Noh, HJ; Park, DH; Woo, YA, 2011
)
0.7

Bioavailability

The mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41. When 6 healthy adult animals were given oltopraz together with cysteine in a crossover study, peak serum concentrations were on average 7 times greater than when the drug was administered alone.

ExcerptReferenceRelevance
" TCDD may produce an increased bioavailability of iron which leads to enhanced DNA single strand breaks and lipid peroxidation in hepatic nuclei."( Factors influencing the induction of DNA single strand breaks in rats by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Lawson, TW; Murray, WJ; Stohs, SJ; Wahba, ZZ, 1989
)
0.28
"The bioavailability of the new antischistosomal agent, oltipraz, was examined under three different dietary conditions in seven healthy males."( Diet-controlled blood levels of oltipraz in healthy male subjects.
Ali, HM; Bennett, JL; Homeida, MM; Sulaiman, SM, 1984
)
0.8
" When 6 healthy adult animals were given oltipraz together with cysteine in a crossover study, peak serum concentrations, areas under the curve and absorption rate constants of oltipraz were on average 7 times greater than when the drug was administered alone."( Effect of cysteine on oltipraz blood levels in green monkeys (Cercopithecus aethiops).
Ali, HM; Bennett, JL; Homeida, MM; Sulaiman, SM, 1984
)
0.85
" There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax."( Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Baker, TM; Benson, AB; Berezin, FK; Dolan, ME; Gupta, E; Mick, R; Olopade, OI; Ratain, MJ, 1995
)
0.83
" Interpretation of OPZ and M3 disposition is confounded by the unknown bioavailability factor; however, the most likely inferences are that bioavailability of OPZ decreases with increasing dose and that metabolism to M3 is saturable."( Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.
Brennan, JM; Gallo, JM; Laub, PB; O'Dwyer, PJ; Szarka, C, 2000
)
0.57
" A second agent, chlorophyllin, impedes the bioavailability of carcinogens by forming molecular complexes and enhances their elimination in the fecal stream."( Strategies for chemoprevention of liver cancer.
Egner, PA; Gange, SJ; Groopman, JD; Jacobson, LP; Kensler, TW; Kuang, SY; Muñoz, A; Qian, GS; Wang, JB; Zhang, BC; Zhu, YR, 2002
)
0.31
"It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41."( Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae, SK; Kim, JW; Kim, SG; Kim, YG; Kim, YH; Lee, MG, 2005
)
0.81
"Poor oral bioavailability limits the use of many chemopreventives in the prevention and treatment of cancer."( Multi-layer polymeric implants for sustained release of chemopreventives.
Aqil, F; Bansal, SS; Gupta, RC; Jeyabalan, J; Kausar, H; Sharma, RJ; Singh, IP; Vadhanam, MV, 2012
)
0.38

Dosage Studied

Oltipraz may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen. Elevations in the levels of some GST isoforms can persist up to 1 week after dosing with oltip Raz.

ExcerptRelevanceReference
" During the second and third weeks of 1,2-dithiole-3-thione feeding, rats were dosed by gavage with 250 micrograms of AFB1/kg five times a week."( Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione.
Curphey, TJ; Eaton, DL; Groopman, JD; Kensler, TW; Roebuck, BD, 1992
)
0.28
" One wk following cessation of dosing with AFB1, oltipraz was removed from the diet, and all rats were fed the AIN-76A diet for the remainder of the experiment."( Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry.
Groopman, JD; Kensler, TW; Liu, YL; Roebuck, BD; Rogers, AE, 1991
)
0.74
" Oltipraz was found to be active in reducing the number of worms significantly only when administered in a higher dosage 2 hours before infection and 7 days after infection."( The prophylactic and curative effect of oltipraz in experimental schistosomiasis mansoni in mice.
Aboul-Atta, AM, 1990
)
1.46
" The latter protocol constitutes a tumorigenic dosing regimen."( Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat.
Groopman, JD; Kensler, TW; Liu, YL; Roebuck, BD; Yager, JD, 1988
)
0.52
"A field trial has been carried out in Sudan to determine the optimum dosage regimen for the use of Oltipraz in the treatment of Schistosoma mansoni in schoolchildren."( Dose-finding trial using Oltipraz to treat schoolchildren infected with Schistosoma mansoni in Gezira, Sudan.
Daffalla, AA; Dixon, HG; el Igail, AB; el Tayeb, M; Fenwick, A; Kardaman, MW, 1985
)
0.79
" Thus, the same parasitological cure could be achieved by oltipraz as well as by praziquantel, but with a lower dosage of oltipraz."( Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon.
Baltes, R; Burchard, GD; Dietrich, M; Kern, P, 1984
)
0.83
" We selected a dosage of 10 mg/kg of metrifonate and 25 mg/kg of niridazole."( [Comparative efficacy of oltipraz (1 dose, 30 mg/kg) and the combination of niridazole (25 mg/kg) and metrifonate (10 mg/kg) against S. haematobium].
Mouchet, F; Rey, JL; Sellin, B; Sellin, E; Simonkovich, E,
)
0.43
" The second intervention strategy utilized a delayed, transient protocol in which oltipraz was fed for 2 weeks beginning 1 week after AFB1 dosing began and ending 2 weeks before AFB1 dosing was completed."( Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz.
Dolan, PM; Egner, PA; Gange, SJ; Groopman, JD; Kensler, TW; Muñoz, A, 1995
)
0.73
" Ideally, clinical chemopreventive interventions use dosing regimens that maximize efficacy while minimizing toxicity."( Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases.
Egner, PA; Kelloff, GJ; Kensler, TW; Primiano, T; Roebuck, BD; Sutter, TR, 1995
)
0.59
" Oltipraz was fed in the diet from one week prior to OH-BBN dosing until sacrifice, six months later."( Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Detrisac, CJ; Kelloff, GJ; Moon, RC; Sigman, CC; Steele, VE; Thomas, CF,
)
1.28
" This inhibition of AFM1 excretion was not seen in animals receiving oltipraz by gavage 24 h prior to dosing with AFB1."( Inhibition of aflatoxin Ml excretion in rat urine during dietary intervention with oltipraz.
Groopman, JD; Kensler, TW; Musser, SM; Scholl, P, 1996
)
0.75
" Although oltipraz has a very short plasma half-life, elevations in the levels of some GST isoforms can persist up to 1 week after dosing with oltipraz."( Chemoprevention by inducers of carcinogen detoxication enzymes.
Kensler, TW, 1997
)
0.7
" To assess the utility of measurements of aflatoxin-albumin adducts to predict risk of hepatocellular carcinoma (HCC), 123 male F344 rats were dosed with 20 microg of AFB1 daily for 5 weeks after randomization into three groups: no intervention; delayed-transient (500 ppm of oltipraz, weeks 2 and 3 relative to AFB1); or persistent (500 ppm oltipraz, weeks -1 to 5)."( Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer.
Dolan, PM; Egner, PA; Gange, SJ; Groopman, JD; Kensler, TW; Muñoz, A; Roebuck, BD; Rogers, AE, 1997
)
0.7
" Induction of glutathione S-transferase, gamma-glutamylcysteine synthetase and DT-diaphorase has been observed in human tissues following the administration of a single oral dosage of oltipraz."( Chemopreventive activity of oltipraz.
Clapper, ML, 1998
)
0.79
" This study was designed to test intermittent dosing schedules using two dosage levels: 500 mg as a single weekly dose and 200 mg as a biweekly dose, each for 30 days."( Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.
Bennett, JL; Bennink, M; Crowell, J; Dimitrov, NV; Gardiner, J; Hawk, E; Leece, CM; Nashawaty, M; Seymour, E; Tompkins, ER, 2001
)
1.75
" Other metabolites derived from the conjugation and/or oxidation of aflatoxin B(1) measured in the urine of dosed rats included aflatoxin P(1), aflatoxin P(1)-glucuronide, aflatoxin Q(1), aflatoxin M(1), 8,9-dihydro-8,9-dihydroxy aflatoxin B(1), aflatoxin B(1)-mercapturic acid, the aflatoxin-cysteine glycine adduct derived from the aflatoxin-glutathione conjugate, aflatoxin M(1)P(1) and the aflatoxin B(1)-dialcohol."( Liquid chromatography electrospray-mass spectrometry of urinary aflatoxin biomarkers: characterization and application to dosimetry and chemoprevention in rats.
Egner, P; Groopman, JD; Kensler, TW; Scholl, PF; Walker, J; Walton, M, 2001
)
0.31
" Two of seven subjects at the 250 mg/m2 dosage required dose reductions, owing to significant fatigue."( Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
Balshem, AM; Clapper, ML; Engstrom, PF; Frucht, H; Goosenberg, EB; Litwin, S; O'Dwyer, PJ; Pfeiffer, GR; Szarka, CE; Yao, KS, 2001
)
0.64
" Individual variations were observed that were not related to Oltipraz dosing or schedule of administration."( Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.
Contreras, ML; Crowell, J; Dimitrov, NV; Madhukar, BV; Meyer-Leece, C, 2002
)
0.77
" The results showed that oltipraz is effective in the inhibition of carcinogenesis prior to or at the same time with Cigarette Smoking Condensate(CSC) treatment; oltipraz can decrease GSTs activity and GST-pi protein content along with its inhibition of HFL carcinogenesis; oltipraz can decrease mp53 expression; oltipraz can prevent but can not reverse the ras gene mutation; oltipraz can induce apoptosis of GLC cell obviously in a dosage of 120 micrograms/ml."( [Studies on inhibition of human lung carcinogenesis in early stage by oltipraz and its effects on some gene expression and regulation].
Bai, H, 1998
)
0.84
" Dose-response studies were undertaken to characterize the cancer chemopreventive activities of several dithiolethiones that are at least as active as oltipraz as inducers."( Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz.
Baumgartner, KJ; Bodreddigari, S; Curphey, TJ; Gange, SJ; Kensler, TW; Li, Y; Roebuck, BD; Sutter, TR; Yan, J, 2003
)
0.75
" This effect was abrogated in Nrf2(-/-) mice dosed with oltipraz, attenuated in mice Nrf2(-/-) mice treated with auraptene and imperatorin, and still significant in Nrf2(-/-) mice treated with isopimpinellin."( Comparison of citrus coumarins on carcinogen-detoxifying enzymes in Nrf2 knockout mice.
Childers, A; Itoh, K; Kleiner, HE; Li, Y; Prince, M; Yamamoto, M, 2009
)
0.6
" Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen."( Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Cho, SH; Choi, JY; Choi, YH; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, MG; Lee, YS; Um, SH; Yu, ES, 2010
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimutagenAn agent that reduces or interferes with the mutagenic actions or effects of a substance.
protective agentSynthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor which interferes with the activity of the enzyme protein tyrosine phosphatases (PTPs), EC 3.1.3.48, involved in the removal of phosphate groups from phosphorylated tyrosine residues on proteins.
schistosomicide drugDrugs that used to treat infestations by flukes (trematodes) of the genus Schistosoma.
neurotoxinA poison that interferes with the functions of the nervous system.
angiogenesis modulating agentAn agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,2-dithiole
pyrazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
Cytochrome P450 1A2Homo sapiens (human)Ki9.00000.00561.15349.0000AID589210
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.41500.00022.45859.9600AID1640021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor erythroid 2-related factor 2Mus musculus (house mouse)CD10.20000.00090.12580.3000AID1248053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
nucleoplasmNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
cytoplasmNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
cytosolNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID679053TP_TRANSPORTER: Western in vivo, liver of Wistar rat1999Carcinogenesis, Dec, Volume: 20, Issue:12
Differential regulation of canalicular multispecific organic anion transporter (cMOAT) expression by the chemopreventive agent oltipraz in primary rat hepatocytes and in rat liver.
AID499301Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 2 to 50 uM after 15 mins in presence of peroxide-destroying enzyme catalase2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID499298Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 25 uM after 15 mins by spectrophotometry2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID499305Inhibition of SHP2 at 10 to 50 uM in presence of arsenate2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID499296Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 2 to 50 uM after 15 mins in presence of 1 mM hydroxyl ion scavenger mannitol2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID679162TP_TRANSPORTER: Branched DNA Assay in vivo, liver of mouse2003Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 31, Issue:11
Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor.
AID1594771Protection against AfB1-induced toxicity in human HepG2 cells assessed as increase in live cell area measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID499300Irreversible inhibition of human PTP1B catalytic subunit at 2 to 50 uM after 15 mins by gel filtration2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID679182TP_TRANSPORTER: Northern blot in vitro, primary rat hepatocyte1999Carcinogenesis, Dec, Volume: 20, Issue:12
Differential regulation of canalicular multispecific organic anion transporter (cMOAT) expression by the chemopreventive agent oltipraz in primary rat hepatocytes and in rat liver.
AID499293Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 50 uM after 15 mins by spectrophotometry in presence of 50 mM sodium phosphate2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID499304Inhibition of SHP2 at 10 to 50 uM in presence of vanadate2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID499295Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 2 to 50 uM after 15 mins in presence of 10 mM metal chelator diethylenetriaminepentaacetic acid2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID589210Mechanism based inhibition of human cytochrome P450 1A2 measured by 7-ethoxyresorufin O-deethylation (EROD)2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID679179TP_TRANSPORTER: Northern blot in vivo, liver of Wistar rat1999Carcinogenesis, Dec, Volume: 20, Issue:12
Differential regulation of canalicular multispecific organic anion transporter (cMOAT) expression by the chemopreventive agent oltipraz in primary rat hepatocytes and in rat liver.
AID237573Increased production of growth hormone2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
QSAR studies on 1,2-dithiole-3-thiones: modeling of lipophilicity, quinone reductase specific activity, and production of growth hormone.
AID679141TP_TRANSPORTER: quantitative PCR in vivo, liver of SD rat2003Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 31, Issue:9
Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.
AID499294Competitive inhibition of human PTP1B at 2 to 50 uM by spectrophotometry2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID680818TP_TRANSPORTER: Northern blot from primary hepatocytes2001Toxicology, Oct-05, Volume: 167, Issue:1
Regulation of biliary drug efflux pump expression by hormones and xenobiotics.
AID679795TP_TRANSPORTER: Branched DNA assay in vivo SD rat, liver2002Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 30, Issue:7
Tissue distribution and chemical induction of multiple drug resistance genes in rats.
AID1299123Reduction of insulin-induced HIF-1 alpha target gene expression in human HCT116 cells assessed as decrease in VEGF expression at 30 uM by RT-PCR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID499302Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 50 uM after 1 hr by spectrophotometry2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID679312TP_TRANSPORTER: Western in vivo, liver of SD rat2003Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 31, Issue:9
Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.
AID1627141Antischistosomal activity against Schistosoma mansoni BH schistosomula assessed as morphological changes after 48 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID499292Competitive inhibition of human PTP1B catalytic subunit assessed as enzyme inactivation at 50 uM after 15 mins by spectrophotometry2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID679143TP_TRANSPORTER: Branched DNA Assay in vivo, liver of WKY rat2003Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 31, Issue:11
Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor.
AID1299117Reduction of insulin-induced HIF-1 alpha expression in human HCT116 cells at 30 uM by western blot analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID499299Inhibition of SHP2 at 10 to 50 uM2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID1248053Activation of Nrf2 in mouse Hepa1c1c7 cells assessed as concentration required to 2 fold induction of NQO1 production after 24 hrs by MTT colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction.
AID1327222Antitumor activity against mouse SVR cells implanted in athymic nude mouse assessed as tumor growth inhibition at 250 mg/kg, po qd for 10 days measured on day 4 relative to control2016European journal of medicinal chemistry, Oct-21, Volume: 1224,5-Diaryl-3H-1,2-dithiole-3-thiones and related compounds as combretastatin A-4/oltipraz hybrids: Synthesis, molecular modelling and evaluation as antiproliferative agents and inhibitors of tubulin.
AID679142TP_TRANSPORTER: Western in vivo, liver of SD rat2003Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 31, Issue:9
Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.
AID1627140Antischistosomal activity against Schistosoma mansoni BH schistosomula assessed as darkening of schistosomula after 48 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID1594772Increase in live cell area in human HepG2 cells measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID499303Irreversible inhibition of human PTP1B catalytic subunit at 50 uM after 1 hr by gel filtration in presence of 100 mM dithiothreitol2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID1627153Antischistosomal activity against Schistosoma mansoni BH schistosomula assessed as rounding appearance of schistosomula after 48 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID237574Increased quinone reductase specific activity2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
QSAR studies on 1,2-dithiole-3-thiones: modeling of lipophilicity, quinone reductase specific activity, and production of growth hormone.
AID679805TP_TRANSPORTER: quantitative PCR in vivo, liver of SD rat2003Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 31, Issue:9
Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.
AID237030Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
QSAR studies on 1,2-dithiole-3-thiones: modeling of lipophilicity, quinone reductase specific activity, and production of growth hormone.
AID1627139Antischistosomal activity against Schistosoma mansoni BH schistosomula assessed as multiple vacuole appearance after 48 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID499297Competitive inhibition of human PTP1B catalytic subunit assessed as residual activity after 15 mins by mass spectroscopic analysis2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.
AID1299120Cytotoxicity against human HCT116 cells at 30 uM2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID1299124Reduction of insulin-induced HIF-1 alpha target gene expression in human HCT116 cells assessed as decrease in Glut-1 expression at 30 uM by RT-PCR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID679058TP_TRANSPORTER: Western in vitro, primary rat hepatocyte1999Carcinogenesis, Dec, Volume: 20, Issue:12
Differential regulation of canalicular multispecific organic anion transporter (cMOAT) expression by the chemopreventive agent oltipraz in primary rat hepatocytes and in rat liver.
AID680322TP_TRANSPORTER: quantitative PCR in vivo, kidney of SD rat2003Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 31, Issue:9
Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (336)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (14.29)18.7374
1990's111 (33.04)18.2507
2000's130 (38.69)29.6817
2010's34 (10.12)24.3611
2020's13 (3.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.30 (24.57)
Research Supply Index5.96 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index42.51 (26.88)
Search Engine Supply Index1.93 (0.95)

This Compound (32.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (7.82%)5.53%
Reviews34 (9.50%)6.00%
Case Studies1 (0.28%)4.05%
Observational0 (0.00%)0.25%
Other295 (82.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fat [NCT01373554]Phase 260 participants (Actual)Interventional2011-05-31Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis [NCT02068339]Phase 3283 participants (Actual)Interventional2014-02-28Completed
A Randomized, Double-Blind, Placebo-Controlled Phase II Multicenter Trial of Oltipraz for the Evaluation of Efficacy and Safety in the Patients With Liver Fibrosis and Cirrhosis Induced by Chronic Hepatitis Type B or C [NCT00956098]Phase 281 participants Interventional2006-02-28Completed
Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers [NCT00006457]Phase 10 participants Interventional2000-08-31Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz [NCT04142749]Phase 3146 participants (Actual)Interventional2019-11-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]